Search clinical trials for: boceprevir placebo

Total 53535 results

Merck Sharp & Dohme LLC

Completed

Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

France, United States, Canada, Germany, Spain, Italy, Puerto Rico
Merck Sharp & Dohme LLC

Terminated

Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

Hepatitis C, Chronic
Indiana University
Merck Sharp & Dohme LLC

Completed

Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation

Liver Transplantation

United States
Erasmus Medical Center
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Completed

Dutch Acute HCV in HIV Study (DAHHS) (DAHHS)

Hepatitis C | Human Immunodeficiency Virus

Netherlands
St Stephens Aids Trust
University of Turin, Italy; University of Liverpool

Completed

Boceprevir and Ucalm (St John&Apos;s Wort)

Hepatitis C

United Kingdom
GlaxoSmithKline

Completed

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

Thrombocytopaenia

United States
Arrowhead Regional Medical Center

Terminated

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

Hepatitis C Infection

United States
University of Calgary
Merck Sharp & Dohme LLC

Completed

Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment (LeeG3)

Hepatitis C

Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma

Oral Mucositis | Oral Squamous Cell Carcinoma

China
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Chronic Hepatitis C
Hu Tsung-Hui

Unknown

Boceprevir Treatment in Liver Pre-transplant HCV Patients

Late Complication From Liver Transplant

Taiwan
University of Modena and Reggio Emilia
Merck Sharp & Dohme LLC

Unknown

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC)

Menopause | Chronic Hepatitis C

Italy
Merck Sharp & Dohme LLC

Completed

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Chronic Hepatitis C Genotype 1
Merck Sharp & Dohme LLC

Completed

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

HIV Infections | Hepatitis C | HCV Infection
Merck Sharp & Dohme LLC

Completed

Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)

Hepatitis C, Chronic
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO) (PROMO)

HCV Infections | Gastric Acid-related Disorders

Netherlands
Theodor Bilharz Research Institute

Unknown

Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection

Genotype 4 Chronic Hepatitis C Infection

Egypt
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (SPRINT-2)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Chronic Hepatitis C
Anna Cruceta

Completed

HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (BOC-HIV)

HIV Infections | Hepatitis C | COINFECTION

Spain
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Boceprevir on HCV-specific T Cell Responses (Boce-Par)

Chronic Hepatitis C

Italy
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Hepatitis C
Debiopharm International SA

Terminated

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Hepatitis C

United States
University of Colorado, Denver

Completed

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

Hepatitis C | HIV

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)

HIV Infections | HCV Infections

Netherlands
Imperial College London

Completed

The Boceprevir and Sildenafil Pharmacokinetics Study

Hepatitis C

United Kingdom
Liver Institute of Virginia
Merck Sharp & Dohme LLC; Chronic Liver Disease Foundation

Unknown

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

End Stage Renal Disease | Chronic Hepatitis C

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Infection, Human Immunodeficiency Virus

United States
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC

Completed

Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation

HCV Infection | Liver Cirrhosis, Experimental

France
Kaohsiung Medical University Chung-Ho Memorial...
National Taiwan University Hospital

Completed

Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy (BOLERO-CB)

Hepatitis C, Chronic

Taiwan
Merck Sharp & Dohme LLC

Withdrawn

A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

Hepatitis C
Merck Sharp & Dohme LLC

Withdrawn

Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (PROVIDE)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Hepatitis C, Chronic | Hepacivirus
ViiV Healthcare
Pfizer

Completed

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Healthy

Belgium
Hoffmann-La Roche

Terminated

An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients

Hepatitis C, Chronic

Hungary
Hoffmann-La Roche

Completed

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

Germany, Austria, Hungary, Romania, Spain, Poland
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
National Institute of Allergy and Infectious Diseases...

Terminated

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Hepatitis | HIV/AIDS

United States
Merck Sharp & Dohme LLC

Completed

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Hepatitis C, Chronic
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
GlaxoSmithKline

Completed

Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity

Dentine Sensitivity

United Kingdom
Merck Sharp & Dohme LLC

Withdrawn

Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

Chronic Hepatitis C

3

Subscribe